Annual report pursuant to Section 13 and 15(d)

LICENSED TECHNOLOGY (Details Textual)

v3.19.1
LICENSED TECHNOLOGY (Details Textual)
1 Months Ended 12 Months Ended
Nov. 04, 2019
USD ($)
Nov. 04, 2018
USD ($)
Jan. 23, 2015
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Finite-Lived Intangible Asset, Useful Life       20 years    
Payable Due Licensor Non current       $ 20,000,000 $ 0  
Amortization of Intangible Assets       1,186,000 534,000 $ 677,000
Payable Due Licensor Current       $ 10,000,000 $ 0  
Abeona Therapeutics LLC [Member]            
Finite-Lived Intangible Asset, Useful Life       20 years    
EB Agreement [Member]            
Number Of License Agreements Research And Development Arrangements       2    
Plasma Technologies, LLC [Member]            
Finite-Lived Intangible Asset, Useful Life       11 years    
License Costs     $ 1,000,000      
REGENXBIO [Member] | Licensing Agreements [Member]            
Finite-Lived Intangible Asset, Useful Life 8 years          
Payable Due Licensor Non current $ 20,000,000 $ 20,000,000        
Guranteed Upfront Payment   20,000,000        
Payment on Execution of Contracts   10,000,000        
Annual Fees   100,000,000        
Milestone Payment   $ 60,000,000        
REGENXBIO [Member] | Licensing Agreements [Member] | Scenario, Forecast [Member]            
Payable Due Licensor Current $ 10,000,000